Summary
Boston Scientific Corporation (BSX) announced on June 25, 2004, the successful public issuance of $600 million in aggregate principal amount of 5.45% senior notes. These notes mature on June 15, 2014, providing long-term financing for the company. The issuance was conducted under an existing shelf registration statement and is governed by agreements with underwriters and an Indenture with JPMorgan Chase Bank as trustee. This financing event provides Boston Scientific with significant capital, likely to support ongoing operations, potential acquisitions, or research and development initiatives. Investors should note the 5.45% interest rate on these senior notes, which represents a cost of debt for the company. The company's ability to raise substantial debt indicates a degree of financial stability and market confidence at the time of the filing.
Key Highlights
- 1Public issuance of $600 million in aggregate principal amount of 5.45% senior notes.
- 2Notes mature on June 15, 2014, providing a 10-year financing term.
- 3Financing conducted under an existing shelf registration statement.
- 4The issuance was made pursuant to an Underwriting Agreement and Terms Agreement dated June 22, 2004.
- 5An Indenture with JPMorgan Chase Bank, as trustee, governs the terms of the notes.
- 6The filing includes exhibits detailing the Underwriting Agreement, Terms Agreement, and the Indenture.